Azarova, Anna M., Gargi Gautam, and Rani E. George. 2011. ‘Emerging Importance of ALK in Neuroblastoma’. Seminars in Cancer Biology 21 (4): 267–75. https://doi.org/10.1016/j.semcancer.2011.09.005.
Beierle, Elizabeth A. n.d. ‘MYCN, Neuroblastoma and Focal Adhesion Kinase (FAK)’. Frontiers in Bioscience (Elite Edition) 3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3171213/.
Bell, Emma, Lindi Chen, Tao Liu, Glenn M. Marshall, John Lunec, and Deborah A. Tweddle. 2010. ‘MYCN Oncoprotein Targets and Their Therapeutic Potential’. Cancer Letters 293 (2): 144–57. https://doi.org/10.1016/j.canlet.2010.01.015.
Bender, Sebastian, Yujie Tang, Anders M. Lindroth, et al. 2013. ‘Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas’. Cancer Cell 24 (5): 660–72. https://doi.org/10.1016/j.ccr.2013.10.006.
Berry, Teeara, William Luther, Namrata Bhatnagar, et al. 2012. ‘The ALKF1174L Mutation Potentiates the Oncogenic Activity of MYCN in Neuroblastoma’. Cancer Cell 22 (1): 117–30. https://doi.org/10.1016/j.ccr.2012.06.001.
Bleggi-Torres, Luiz Fernando, Lúcia de Noronha, Elizabeth Schneider Gugelmin, et al. 2001. ‘Accuracy of the Smear Technique in the Cytological Diagnosis of 650 Lesions of the Central Nervous System’. Diagnostic Cytopathology 24 (4): 293–95. https://doi.org/10.1002/dc.1062.
Blümcke, Ingmar, Eleonora Aronica, Albert Becker, et al. 2016. ‘Low-Grade Epilepsy-Associated Neuroepithelial Tumours — the 2016 WHO Classification’. Nature Reviews Neurology 12 (12): 732–40. https://doi.org/10.1038/nrneurol.2016.173.
Brodeur, Garrett M. 2003. ‘Neuroblastoma: Biological Insights into a Clinical Enigma’. Nature Reviews Cancer 3 (3): 203–16. https://doi.org/10.1038/nrc1014.
Brodeur, Garrett M., and Rochelle Bagatell. 2014. ‘Mechanisms of Neuroblastoma Regression’. Nature Reviews Clinical Oncology 11 (12): 704–13. https://doi.org/10.1038/nrclinonc.2014.168.
Brown, Christine E., Darya Alizadeh, Renate Starr, et al. 2016. ‘Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy’. New England Journal of Medicine 375 (26): 2561–69. https://doi.org/10.1056/NEJMoa1610497.
Buckner, Tyler, Julie Blatt, and Scott Victor Smith. 2006. ‘The Autopsy in Pediatrics and Pediatric Oncology: A Single-Institution Experience’. Pediatric and Developmental Pathology 9 (5): 374–80. https://doi.org/10.2350/06-02-0047.1.
Burkhart, C. A., A. J. Cheng, J. Madafiglio, et al. 2003. ‘Effects of MYCN Antisense Oligonucleotide Administration on Tumorigenesis in a Murine Model of Neuroblastoma’. JNCI Journal of the National Cancer Institute 95 (18): 1394–403. https://doi.org/10.1093/jnci/djg045.
Chen, L., N. Iraci, S. Gherardi, et al. 2010. ‘P53 Is a Direct Transcriptional Target of MYCN in Neuroblastoma’. Cancer Research 70 (4): 1377–88. https://doi.org/10.1158/0008-5472.CAN-09-2598.
Chhabda, Sahil, Olivia Carney, Felice D’Arco, Thomas S. Jacques, and Kshitij Mankad. 2016. ‘The 2016 World Health Organization Classification of Tumours of the Central Nervous System: What the Paediatric Neuroradiologist Needs to Know’. Quantitative Imaging in Medicine and Surgery 6 (5): 486–89. https://doi.org/10.21037/qims.2016.10.01.
‘Children’s Cancer Statistics | Cancer Research UK’. n.d. http://www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers.
Cossu, Irene, Gianluca Bottoni, Monica Loi, et al. 2015. ‘Neuroblastoma-Targeted Nanocarriers Improve Drug Delivery and Penetration, Delay Tumor Growth and Abrogate Metastatic Diffusion’. Biomaterials 68 (November): 89–99. https://doi.org/10.1016/j.biomaterials.2015.07.054.
Ellison, David W., Olabisi E. Onilude, Janet C. Lindsey, et al. 2005. ‘β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children’s Cancer Study Group Brain Tumour Committee’. Journal of Clinical Oncology 23 (31): 7951–57. https://doi.org/10.1200/JCO.2005.01.5479.
Evans, A E, E Baum, and R Chard. 1981. ‘Do Infants with Stage IV-S Neuroblastoma Need Treatment?’ Archives of Disease in Childhood 56 (4): 271–74. https://doi.org/10.1136/adc.56.4.271.
Fisher, Jonathan, Pierre Abramowski, Nisansala Dilrukshi Wisidagamage Don, et al. 2017. ‘Avoidance of On-Target Off-Tumor Activation Using a Co-Stimulation-Only Chimeric Antigen Receptor’. Molecular Therapy 25 (5): 1234–47. https://doi.org/10.1016/j.ymthe.2017.03.002.
Garrett M. Brodeur, Robert C. Seeger, Manfred Schwab, Harold E. Varmus and J. Michael Bishop. 1984. ‘Amplification of N-Myc in Untreated Human Neuroblastomas Correlates with Advanced Disease Stage’. Science 224 (4653): 1121–24. http://www.jstor.org/stable/1692440.
Ghorashian, Sara, Persis Amrolia, and Paul Veys. 2018. ‘Open Access? Widening Access to Chimeric Antigen Receptor (CAR) Therapy for ALL’. Experimental Hematology 66 (October): 5–16. https://doi.org/10.1016/j.exphem.2018.07.002.
Gibson, Paul, Yiai Tong, Giles Robinson, et al. 2010. ‘Subtypes of Medulloblastoma Have Distinct Developmental Origins’. Nature 468 (7327): 1095–99. https://doi.org/10.1038/nature09587.
Goschzik, Tobias, Marco Gessi, Verena Dreschmann, et al. 2017. ‘Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma’. Journal of Neuropathology & Experimental Neurology, ahead of print, January 9. https://doi.org/10.1093/jnen/nlw116.
Greaves, Mel F., and Joe Wiemels. 2003. ‘Origins of Chromosome Translocations in Childhood Leukaemia’. Nature Reviews Cancer 3 (9): 639–49. https://doi.org/10.1038/nrc1164.
Guglielmi, L, C Cinnella, M Nardella, et al. 2014. ‘MYCN Gene Expression Is Required for the Onset of the Differentiation Programme in Neuroblastoma Cells’. Cell Death & Disease 5 (2): e1081–e1081. https://doi.org/10.1038/cddis.2014.42.
Gump, Jacob M, Andrew M Donson, Diane K Birks, et al. 2015. ‘Identification of Targets for Rational Pharmacological Therapy in Childhood Craniopharyngioma’. Acta Neuropathologica Communications 3 (1). https://doi.org/10.1186/s40478-015-0211-5.
Hanahan, Douglas, and Robert A Weinberg. 2000. ‘The Hallmarks of Cancer’. Cell 100 (1): 57–70. https://doi.org/10.1016/S0092-8674(00)81683-9.
Hanahan, Douglas, and Robert A. Weinberg. 2011. ‘Hallmarks of Cancer: The Next Generation’. Cell 144 (5): 646–74. https://doi.org/10.1016/j.cell.2011.02.013.
Hashizume, Rintaro, Noemi Andor, Yuichiro Ihara, et al. 2014. ‘Pharmacologic Inhibition of Histone Demethylation as a Therapy for Pediatric Brainstem Glioma’. Nature Medicine 20 (12): 1394–96. https://doi.org/10.1038/nm.3716.
Hasle, Henrik, and Charlotte M. Niemeyer. 2011. ‘Advances in the Prognostication and Management of Advanced MDS in Children’. British Journal of Haematology 154 (2): 185–95. https://doi.org/10.1111/j.1365-2141.2011.08724.x.
Hill, Rebecca M., Sanne Kuijper, Janet C. Lindsey, et al. 2015. ‘Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable Disease’. Cancer Cell 27 (1): 72–84. https://doi.org/10.1016/j.ccell.2014.11.002.
Hourigan, Christopher S., and Judith E. Karp. 2013. ‘Minimal Residual Disease in Acute Myeloid Leukaemia’. Nature Reviews Clinical Oncology 10 (8): 460–71. https://doi.org/10.1038/nrclinonc.2013.100.
Huang, M., and W. A. Weiss. 2013. ‘Neuroblastoma and MYCN’. Cold Spring Harbor Perspectives in Medicine 3 (10): a014415–a014415. https://doi.org/10.1101/cshperspect.a014415.
Huber, Katrin, Chaya Kalcheim, and Klaus Unsicker. 2009. ‘The Development of the Chromaffin Cell Lineage from the Neural Crest’. Autonomic Neuroscience 151 (1): 10–16. https://doi.org/10.1016/j.autneu.2009.07.020.
Hubert, Christopher G., Maricruz Rivera, Lisa C. Spangler, et al. 2016. ‘A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found’. Cancer Research 76 (8): 2465–77. https://doi.org/10.1158/0008-5472.CAN-15-2402.
Hunger, Stephen P., and Charles G. Mullighan. 2015. ‘Acute Lymphoblastic Leukemia in Children’. New England Journal of Medicine 373 (16): 1541–52. https://doi.org/10.1056/NEJMra1400972.
International Agency for Research on Cancer. 2016. WHO Classification of Tumours of the Central Nervous System. Revised 4th edition. Edited by David N. Louis, Hiroko Ohgaki, O. D. Wiestler, and W. K. Cavenee. International Agency for Research on Cancer.
Johnson, Laura A, and Carl H June. 2017. ‘Driving Gene-Engineered T Cell Immunotherapy of Cancer’. Cell Research 27 (1): 38–58. https://doi.org/10.1038/cr.2016.154.
Kirsti Sirkiä, Ulla M. Saarinen‐Pihkala, Liisa Hovi, Hannu Sariola. 1998. ‘Autopsy in Children with Cancer Who Die While in Terminal Care’. Medical and Pediatric Oncology 30 (5): 284–89. https://doi.org/10.1002/(SICI)1096-911X(199805)30:5<284::AID-MPO4>3.0.CO;2-B.
Klebanoff, Christopher A, Steven A Rosenberg, and Nicholas P Restifo. 2016. ‘Prospects for Gene-Engineered T Cell Immunotherapy for Solid Cancers’. Nature Medicine 22 (1): 26–36. https://doi.org/10.1038/nm.4015.
Koebel, Catherine M., William Vermi, Jeremy B. Swann, et al. 2007. ‘Adaptive Immunity Maintains Occult Cancer in an Equilibrium State’. Nature 450 (7171): 903–7. https://doi.org/10.1038/nature06309.
Korshunov, AndreySturm, DominikRyzhova, MarinaHovestadt, VolkerGessi, Marco. n.d. ‘Embryonal Tumor with Abundant Neuropil and True Rosettes (ETANTR), Ependymoblastoma, and Medulloepithelioma Share Molecular Similarity and Comprise a Single Clinicopathological Entity’. Acta Neuropathologica 128 (8): 279–89. https://search.proquest.com/docview/1545765655?OpenUrlRefId=info:xri/sid:primo&accountid=14511.
Kotrova, Michaela, Jan Trka, Michael Kneba, and Monika Brüggemann. 2017. ‘Is Next-Generation Sequencing the Way to Go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?’ Molecular Diagnosis & Therapy 21 (5): 481–92. https://doi.org/10.1007/s40291-017-0277-9.
Larson, Jon D., Lawryn H. Kasper, Barbara S. Paugh, et al. 2018. ‘Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression’. Cancer Cell, ahead of print, December. https://doi.org/10.1016/j.ccell.2018.11.015.
Lee, Tong Ihn, and Richard A. Young. 2013. ‘Transcriptional Regulation and Its Misregulation in Disease’. Cell 152 (6): 1237–51. https://doi.org/10.1016/j.cell.2013.02.014.
Lewis, P. W., M. M. Muller, M. S. Koletsky, et al. 2013. ‘Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma’. Science 340 (6134): 857–61. https://doi.org/10.1126/science.1232245.
Liu, Zhihui, and Carol J. Thiele. 2012. ‘ALK and MYCN: When Two Oncogenes Are Better than One’. Cancer Cell 21 (3): 325–26. https://doi.org/10.1016/j.ccr.2012.03.004.
Lord, Christopher J, and Alan Ashworth. 2010. ‘Biology-Driven Cancer Drug Development: Back to the Future’. BMC Biology 8 (1). https://doi.org/10.1186/1741-7007-8-38.
Lu, Benjamin, Brooke Green, Jacqueline Farr, Flávia Lopes, and Terence Van Raay. 2016. ‘Wnt Drug Discovery: Weaving Through the Screens, Patents and Clinical Trials’. Cancers 8 (9). https://doi.org/10.3390/cancers8090082.
Mackall, Crystal L., Melinda S. Merchant, and Terry J. Fry. 2014. ‘Immune-Based Therapies for Childhood Cancer’. Nature Reviews Clinical Oncology 11 (12): 693–703. https://doi.org/10.1038/nrclinonc.2014.177.
Majzner, Robbie G., Sabine Heitzeneder, and Crystal L. Mackall. 2017. ‘Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers’. Cancer Cell 31 (4): 476–85. https://doi.org/10.1016/j.ccell.2017.03.002.
Marabelle, Aurélien, Vincent Sapin, Raphaël Rousseau, Brigitte Periquet, François Demeocq, and Justyna Kanold. 2009. ‘Hypercalcemia and 13- -Retinoic Acid in Post-Consolidation Therapy of Neuroblastoma’. Pediatric Blood & Cancer 52 (2): 280–83. https://doi.org/10.1002/pbc.21768.
Martinez-Barbera, Juan Pedro, and Cynthia L. Andoniadou. 2016. ‘Concise Review: Paracrine Role of Stem Cells in Pituitary Tumors: A Focus on Adamantinomatous Craniopharyngioma’. STEM CELLS 34 (2): 268–76. https://doi.org/10.1002/stem.2267.
Martinez-Barbera, Juan Pedro, and Rolf Buslei. 2015. ‘Adamantinomatous Craniopharyngioma: Pathology, Molecular Genetics and Mouse Models’. Journal of Pediatric Endocrinology and Metabolism 28 (1–2). https://doi.org/10.1515/jpem-2014-0442.
Matthay, Katherine K., Judith G. Villablanca, Robert C. Seeger, et al. 1999. ‘Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13- -Retinoic Acid’. New England Journal of Medicine 341 (16): 1165–73. https://doi.org/10.1056/NEJM199910143411601.
Milne, Thomas A. 2017. ‘Mouse Models of MLL Leukemia: Recapitulating the Human Disease’. Blood 129 (16): 2217–23. https://doi.org/10.1182/blood-2016-10-691428.
Morsut, Leonardo, Kole T. Roybal, Xin Xiong, et al. 2016. ‘Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors’. Cell 164 (4): 780–91. https://doi.org/10.1016/j.cell.2016.01.012.
Mossé, Yaël P., Marci Laudenslager, Luca Longo, et al. 2008. ‘Identification of ALK as a Major Familial Neuroblastoma Predisposition Gene’. Nature 455 (7215): 930–35. https://doi.org/10.1038/nature07261.
Nataliya Zhukova. 2013. ‘Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma’. Journal of Clinical Oncology 31 (23). https://doi.org/10.1200/JCO.2012.48.5052.
Nature Reviews Immunology. 2012. 12 (4). https://www.nature.com/nri/volumes/12/issues/4.
Niemeyer, Charlotte Marie, and Christian Peter Kratz. 2008. ‘Paediatric Myelodysplastic Syndromes and Juvenile Myelomonocytic Leukaemia: Molecular Classification and Treatment Options’. British Journal of Haematology 140 (6): 610–24. https://doi.org/10.1111/j.1365-2141.2007.06958.x.
Niklison-Chirou, Maria Victoria, Ida Erngren, Mikael Engskog, et al. 2017. ‘TAp73 Is a Marker of Glutamine Addiction in Medulloblastoma’. Genes & Development 31 (17): 1738–53. https://doi.org/10.1101/gad.302349.117.
Northcott, Paul A., Andrey Korshunov, Stefan M. Pfister, and Michael D. Taylor. 2012. ‘The Clinical Implications of Medulloblastoma Subgroups’. Nature Reviews Neurology 8 (6): 340–51. https://doi.org/10.1038/nrneurol.2012.78.
O’Connor, David, Amir Enshaei, Jack Bartram, et al. 2018a. ‘Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia’. Journal of Clinical Oncology 36 (1): 34–43. https://doi.org/10.1200/JCO.2017.74.0449.
O’Connor, David, Amir Enshaei, Jack Bartram, et al. 2018b. ‘Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia’. Journal of Clinical Oncology 36 (1): 34–43. https://doi.org/10.1200/JCO.2017.74.0449.
Pastorino, Fabio, Danilo Marimpietri, Chiara Brignole, et al. 2007. ‘Ligand-Targeted Liposomal Therapies of Neuroblastoma’. Current Medicinal Chemistry 14 (29): 3070–78. https://doi.org/10.2174/092986707782793916.
Pathania, Manav, Nicolas De Jay, Nicola Maestro, et al. 2017. ‘H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas’. Cancer Cell 32 (5): 684-700.e9. https://doi.org/10.1016/j.ccell.2017.09.014.
Pfister, Stefan, Marc Remke, Mirco Castoldi, et al. 2009. ‘Novel Genomic Amplification Targeting the microRNA Cluster at 19q13.42 in a Pediatric Embryonal Tumor with Abundant Neuropil and True Rosettes’. Acta Neuropathologica 117 (4): 457–64. https://doi.org/10.1007/s00401-008-0467-y.
Phoenix, Timothy N., Deanna M. Patmore, Scott Boop, et al. 2016. ‘Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype’. Cancer Cell 29 (4): 508–22. https://doi.org/10.1016/j.ccell.2016.03.002.
Qasim, Waseem, Hong Zhan, Sujith Samarasinghe, et al. 2017. ‘Molecular Remission of Infant B-ALL after Infusion of Universal TALEN Gene-Edited CAR T Cells’. Science Translational Medicine 9 (374). https://doi.org/10.1126/scitranslmed.aaj2013.
Qiao, Jingbo, Pritha Paul, Sora Lee, et al. 2012. ‘PI3K/AKT and ERK Regulate Retinoic Acid-Induced Neuroblastoma Cellular Differentiation’. Biochemical and Biophysical Research Communications 424 (3): 421–26. https://doi.org/10.1016/j.bbrc.2012.06.125.
Rasaiyaah, Jane, Christos Georgiadis, Roland Preece, Ulrike Mock, and Waseem Qasim. 2018. ‘TCRαβ/CD3 Disruption Enables CD3-Specific Antileukemic T Cell Immunotherapy’. JCI Insight 3 (13). https://doi.org/10.1172/jci.insight.99442.
Reynolds, C.Patrick, Katherine K. Matthay, Judith G. Villablanca, and Barry J. Maurer. 2003. ‘Retinoid Therapy of High-Risk Neuroblastoma’. Cancer Letters 197 (1–2): 185–92. https://doi.org/10.1016/S0304-3835(03)00108-3.
Richmond, A., and Y. Su. 2008. ‘Mouse Xenograft Models vs GEM Models for Human Cancer Therapeutics’. Disease Models and Mechanisms 1 (2–3): 78–82. https://doi.org/10.1242/dmm.000976.
Sadelain, Michel, Isabelle Rivière, and Stanley Riddell. 2017. ‘Therapeutic T Cell Engineering’. Nature 545 (7655): 423–31. https://doi.org/10.1038/nature22395.
Schwab, M. 2004. ‘MYCN in Neuronal Tumours’. Cancer Letters 204 (2): 179–87. https://doi.org/10.1016/S0304-3835(03)00454-3.
Schwalbe, Ed. C., James T. Hayden, Hazel A. Rogers, et al. 2013. ‘Histologically Defined Central Nervous System Primitive Neuro-Ectodermal Tumours (CNS-PNETs) Display Heterogeneous DNA Methylation Profiles and Show Relationships to Other Paediatric Brain Tumour Types’. Acta Neuropathologica 126 (6): 943–46. https://doi.org/10.1007/s00401-013-1206-6.
Schwalbe, Edward C, Janet C Lindsey, Sirintra Nakjang, et al. 2017. ‘Novel Molecular Subgroups for Clinical Classification and Outcome Prediction in Childhood Medulloblastoma: A Cohort Study’. The Lancet Oncology 18 (7): 958–71. https://doi.org/10.1016/S1470-2045(17)30243-7.
Schwartzentruber, Jeremy, Andrey Korshunov, Xiao-Yang Liu, et al. 2012. ‘Driver Mutations in Histone H3.3 and Chromatin Remodelling Genes in Paediatric Glioblastoma’. Nature 482 (7384): 226–31. https://doi.org/10.1038/nature10833.
Sidell, Neil. 1982. ‘Retinoic Acid-Induced Growth Inhibition and Morphologic Differentiation of Human Neuroblastoma Cells In Vitro’. JNCI: Journal of the National Cancer Institute, ahead of print. https://doi.org/10.1093/jnci/68.4.589.
Slany, R K. 2016. ‘The Molecular Mechanics of Mixed Lineage Leukemia’. Oncogene 35 (40): 5215–23. https://doi.org/10.1038/onc.2016.30.
Stone, T. J., and T. S. Jacques. 2015. ‘Medulloblastoma: Selecting Children for Reduced Treatment’. Neuropathology and Applied Neurobiology 41 (2): 106–8. https://doi.org/10.1111/nan.12193.
Strebhardt, Klaus, and Axel Ullrich. 2008. ‘Paul Ehrlich’s Magic Bullet Concept: 100 Years of Progress’. Nature Reviews Cancer 8 (6): 473–80. https://doi.org/10.1038/nrc2394.
Sturm, Dominik, Brent A. Orr, Umut H. Toprak, et al. 2016. ‘New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs’. Cell 164 (5): 1060–72. https://doi.org/10.1016/j.cell.2016.01.015.
Sturm, Dominik, Hendrik Witt, Volker Hovestadt, et al. 2012. ‘Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma’. Cancer Cell 22 (4): 425–37. https://doi.org/10.1016/j.ccr.2012.08.024.
Taylor, Michael DNorthcott, Paul AKorshunov, AndreyRemke, MarcCho, Yoon-jae. n.d. ‘Molecular Subgroups of Medulloblastoma: The Current Consensus’. Acta Neuropathologica 123 (3): 465–72. https://search.proquest.com/docview/928783888?rfr_id=info%3Axri%2Fsid%3Aprimo.
Vogelstein, B., N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz, and K. W. Kinzler. 2013a. ‘Cancer Genome Landscapes’. Science 339 (6127): 1546–58. https://doi.org/10.1126/science.1235122.
Vogelstein, B., N. Papadopoulos, V. E. Velculescu, S. Zhou, L. A. Diaz, and K. W. Kinzler. 2013b. ‘Cancer Genome Landscapes’. Science 339 (6127): 1546–58. https://doi.org/10.1126/science.1235122.
Vora, Ajay, Nick Goulden, Chris Mitchell, et al. 2014. ‘Augmented Post-Remission Therapy for a Minimal Residual Disease-Defined High-Risk Subgroup of Children and Young People with Clinical Standard-Risk and Intermediate-Risk Acute Lymphoblastic Leukaemia (UKALL 2003): A Randomised Controlled Trial’. The Lancet Oncology 15 (8): 809–18. https://doi.org/10.1016/S1470-2045(14)70243-8.
Vora, Ajay, Nick Goulden, Rachel Wade, et al. 2013. ‘Treatment Reduction for Children and Young Adults with Low-Risk Acute Lymphoblastic Leukaemia Defined by Minimal Residual Disease (UKALL 2003): A Randomised Controlled Trial’. The Lancet Oncology 14 (3): 199–209. https://doi.org/10.1016/S1470-2045(12)70600-9.
Wegman-Ostrosky, Talia, and Sharon A. Savage. 2017. ‘The Genomics of Inherited Bone Marrow Failure: From Mechanism to the Clinic’. British Journal of Haematology 177 (4): 526–42. https://doi.org/10.1111/bjh.14535.
Weinberg, Robert A. 2014. The Biology of Cancer. 2nd ed. Garland Science.
Wright, James Homer. 1910. ‘NEUROCYTOMA OR NEUROBLASTOMA, A KIND OF TUMOR NOT GENERALLY RECOGNIZED’. The Journal of Experimental Medicine 12 (4). https://doi.org/10.1084/jem.12.4.556.
Yang, LiqunKe, Xiao-XueXuan, FanTan, JuanHou, Jianbing. n.d. ‘PHOX2B Is Associated with Neuroblastoma Cell Differentiation’. Cancer Biotherapy & Radiopharmaceuticals 31: 44–51. https://doi.org/10.1089/cbr.2015.1952.
Yong, Carmen S M, Valerie Dardalhon, Christel Devaud, Naomi Taylor, Phillip K Darcy, and Michael H Kershaw. 2017. ‘CAR T-Cell Therapy of Solid Tumors’. Immunology and Cell Biology 95 (4): 356–63. https://doi.org/10.1038/icb.2016.128.
Zelent, Arthur, Mel Greaves, and Tariq Enver. 2004. ‘Role of the TEL-AML1 Fusion Gene in the Molecular Pathogenesis of Childhood Acute Lymphoblastic Leukaemia’. Oncogene 23 (24): 4275–83. https://doi.org/10.1038/sj.onc.1207672.
Zhu, Shizhen, Jeong-Soo Lee, Feng Guo, et al. 2012. ‘Activated ALK Collaborates with MYCN in Neuroblastoma Pathogenesis’. Cancer Cell 21 (3): 362–73. https://doi.org/10.1016/j.ccr.2012.02.010.
